{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:22:58Z","timestamp":1788960178899,"version":"build-2803163510"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,6]]},"abstract":"<jats:p>Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an immune-mediated inflammatory demyelinating disease of the central nervous system. This study aimed to delineate the clinical manifestations, imaging features, and long-term outcomes in Chinese patients with MOGAD and analyze the recurrence-associated factors. The phenotypic and neuroimaging characteristics of 15 Han Chinese patients with MOGAD were retrospectively analyzed. Demyelinating attacks, MOG antibodies in the cerebrospinal fluid\/serum, response to immunotherapy, follow-up outcomes, and recurrence-associated factors were recorded. The median age at disease onset was 34 years (range, 4\u201365 years). The most common initial presentations included vision loss (10\/15, 66.7%) and seizures (5\/15, 33.3%). Serum MOG-Ab titers in 14\/15 cases were higher than those in the cerebrospinal fluid and were detected in 3\/6 relapsed patients. Brain magnetic resonance imaging during acute attacks showed lesions in 10\/15 patients (66.7%), mostly in the cortex\/subcortical white matter (5\/15, 33.3%). Recurrence occurred in 6\/15 patients (40.0%); in 4 patients, recurrence occurred shortly after immunotherapy discontinuation. Residual neurological deficits were present in 5\/15 patients (33.3%), including visual impairment, incapacitation, cognitive impairment, and speech reduction. Optic neuritis was the most common clinical manifestation of MOGAD. magnetic resonance imaging findings were heterogeneous and the cerebral cortex\/subcortical white matter was the most susceptible brain region. Although patients in the acute phase responded well to methylprednisolone pulse therapy, the long-term recurrence rate was high. Consistently detected serum MOG antibodies and inappropriate maintenance immunotherapy may be associated with recurrence, and residual neurological deficits should not be ignored.<\/jats:p>","DOI":"10.1097\/md.0000000000035391","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T12:02:10Z","timestamp":1696593730000},"page":"e35391","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["Clinical characteristics and long-term follow-up outcomes of myelin oligodendrocyte glycoprotein antibody-associated disease in Han Chinese participants"],"prefix":"10.1097","volume":"102","author":[{"given":"Wei","family":"Zeng","sequence":"first","affiliation":[{"name":"Department of Neurology, Liuzhou People\u2019s Hospital, Liuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurology, First Affiliated Hospital of Guangxi Medical University, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Wu","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Guangdong Medical University, Zhanjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Liuzhou People\u2019s Hospital, Liuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Shenzhen University, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqun","family":"Ren","sequence":"additional","affiliation":[{"name":"School of Nursing, Guangxi University of Chinese Medicine, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daxue","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Nursing, Anhui Medical University, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baorong","family":"Lian","sequence":"additional","affiliation":[{"name":"Shantou University Medical College, Shantou University, Shantou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Hu","sequence":"additional","affiliation":[{"name":"Hunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2836-9347","authenticated-orcid":false,"given":"Liming","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Shenzhen University, Shenzhen, China"},{"name":"Hunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, China"},{"name":"Clinical College of the Shenzhen Second People\u2019s Hospital, Anhui Medical University, Shenzhen, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","article-title":"Neurological update: MOG antibody disease.","volume":"266","author":"Wynford-Thomas","year":"2019","journal-title":"J Neurol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease:a UK study.","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"R3-20250504","first-page":"jnnp-2020-324422","article-title":"Anti-MOG antibody- associated disorders: differences in clinical profiles and prognosis in Japan and Germany.","author":"Liu","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R4-20250504","first-page":"44","article-title":"Follow-up study on Chinese children with relapsing MOG-IgG-associated central nervous system demyelination.","volume":"28","author":"Zhou","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"R5-20250504","first-page":"86","article-title":"Chinese expert consensus on diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein-IgG associated disorders.","volume":"27","author":"Qiu","year":"2020","journal-title":"Chin J Neuroimmunol & Neurol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1162647","DOI":"10.3389\/fimmu.2023.1162647","article-title":"Pediatric myelin oligodendrocyte glycoprotein antibody-associated disease in southern China: analysis of 93 cases.","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"R7-20250504","first-page":"997","article-title":"Clinical and imaging features of 13 children with myelin oligodendrocyte glycoprotein antibody- associated encephalomyelitis.","volume":"34","author":"Xu","year":"2019","journal-title":"Chin J Appl Clin Pediatr"},{"key":"R8-20250504","first-page":"174","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein antibody- positive optic neuritis.","volume":"55","author":"Song","year":"2019","journal-title":"Chin J Ophthalmol"},{"key":"R9-20250504","first-page":"467","article-title":"Analysis of the clinical feature and prognosis of the NMOSD-ON and MOGAD-ON with thyroid antibody.","volume":"29","author":"Liu","year":"2022","journal-title":"Chin J Neuroimmunol Neurol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10072-019-04095-9","article-title":"Clinical characteristics and long-term follow-up of seven cases of anti-GABABR encephalitis in patients of Han Chinese descent.","volume":"41","author":"Zeng","year":"2020","journal-title":"Neurol Sci"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10072-020-04482-7","article-title":"Clinical characteristics and long-term prognosis of relapsing anti-N-methyl-D-aspartate receptor encephalitis: a retrospective, multicenter, self-controlled study.","volume":"42","author":"Zeng","year":"2021","journal-title":"Neurol Sci"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease.","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann Neurol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease.","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3389\/fneur.2019.00415","article-title":"Seizure and myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis in a retrospective cohort of chinese patients.","volume":"10","author":"Zhong","year":"2019","journal-title":"Front Neurol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults.","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"R17-20250504","first-page":"74","article-title":"S4B-5 effect of fasudil on remyelination following the cuprizone-induced demyelination in male C57BL\/6 Mice.","volume":"8","author":"Wang","year":"2018","journal-title":"Acta Neuropharmacologica"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1007\/s00115-018-0607-0","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.","volume":"89","author":"Jarius","year":"2018","journal-title":"Nervenarzt"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0037-1604404","article-title":"MOG spectrum disorders and role of MOG-antibodies in clinical practice.","volume":"49","author":"Hennes","year":"2018","journal-title":"Neuropediatrics"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1177\/1352458519893093","article-title":"MRI differences between MOG antibody disease and AQP4 NMOSD.","volume":"26","author":"Salama","year":"2020","journal-title":"Mult Scler"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/aww350","article-title":"Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"116430","DOI":"10.1016\/j.jns.2019.116430","article-title":"Different magnetic resonance imaging features between MOG antibody-and AQP4 antibody- mediated disease: a Chinese cohort study.","volume":"405","author":"Chen","year":"2019","journal-title":"J Neurol Sci"},{"key":"R23-20250504","first-page":"334","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein antibody associated myelitis.","volume":"100","author":"Zhangbao","year":"2020","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","article-title":"E.U. paediatric MOG consortium consensus: part 5-Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"885218","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management.","volume":"13","author":"Sechi","year":"2022","journal-title":"Front Neurol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jocn.2016.12.022","article-title":"Azathioprine therapy in a case of pediatric multiple sclerosis that was seropositive for MOG-IgG.","volume":"38","author":"Zhou","year":"2017","journal-title":"J Clin Neurosci"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders.","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody- associated disease.","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajo.2022.01.015","article-title":"Vision prognosis and associated factors of optic neuritis in dependence of glial autoimmune antibodies.","volume":"239","author":"Yang","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"9769","DOI":"10.3390\/ijms23179769","article-title":"Treatment and relapse prevention of typical and atypical optic neuritis.","volume":"23","author":"Saitakis","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:05:22Z","timestamp":1746327922000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":30,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035391","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,6]]}}}